Aim immunotech announces positive data from phase 1 study evaluating ampligen® for the treatment of stage 4 metastatic triple negative breast cancer

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (ckm) therapy, including ampligen and pembrolizumab, successfully met primary endpoint

AIM Ratings Summary

AIM Quant Ranking